摘要
目的 观察益气扶正方联合恩替卡韦结合治疗乙肝e抗原(HBeAg)阳性慢性乙型肝炎(CHB)临床疗效。方法 将我院162例HBeAg阳性CHB患者随机分为研究组与对照组各81例。对照组口服用恩替卡韦治疗,研究组服用益气扶正方联合恩替卡韦治疗。比较两组临床疗效,中医证候积分,病毒学应答[乙肝病毒(HBV) DNA转阴率、HBeAg、乙肝表面抗原(HBsAg)载量]、HBeAg血清学应答(血清学转换率)、生物化学应答[谷丙转氨酸(ALT)复常率,ALT、谷草转氨酶(AST)、白蛋白(ALB)]水平。结果 治疗后,研究组总有效率高于对照组(P<0.05);两组中医证候积分、HBeAg、HBsAg载量、ALT、AST水平低于治疗前,研究组中医证候积分、HBeAg、HBsAg载量、ALT、AST水平低于对照组(P<0.05);研究组HBeAg血清转换率、ALT复常率高于对照组(P<0.05);两组ALB水平高于治疗前;研究组ALB水平高于对照组(P<0.05)。结论 益气扶正方结合恩替卡韦对HBeAg阳性CHB患者疗效优于恩替卡韦组,能降低中医证候积分,提高生物化学应答和HBeAg血清学应答,降低HBeAg、HBsAg载量,但对HBV DNA转阴率作用不大。
Objective To observe the clinical effects of Yiqi Fuzheng Prescription combined with entecavir on chronic hepatitis B(CHB)with positive HBeAg.Methods A total of 162 HBeAg positive CHB patients were randomly divided into study group and control group,with 81 cases in each group.Control group took entecavir orally,and study group took Yiqi Fuzheng Prescription on the basis of control group.The total effective rate,TCM syndrome score,virology response[hepatitis B virus(HBV)DNA negative conversion rate,HBeAg,hepatitis B surface antigen(HBsAg)load],HBeAg serological response(serological conversion rate),biochemical response[alanine aminotransferase(ALT)normalization rate,ALT,aspartate Transaminase(AST),albumin(ALB)]levels were compared between the two groups.Results The total effective rate of research group was higher than that of control group(P<0.05);after treatment,the TCM syndrome score,HBeAg,HBsAg load,ALT,and AST levels in both groups were lower than before treatment,and were lower in study group than control group(P<0.05);the HBeAg serum conversion rate and ALT normalization rate in study group were higher than those in control group(P<0.05);the levels of ALB in both groups after treatment were higher than before treatment;and was higher in study group than control group(P<0.05).Conclusion Yiqi Fuzheng Prescription combined with entecavir is more effective than entecavir in treatment of CHB with positive HBeAg.It can drop TCMsyndrome score,improve biochemical response and HBeAg serological response,reduce the load of HBeAg and HBsAg,but has little effect on the negative rate of HBV DNA.
作者
陈红旭
汪俊科
CHEN Hong-xu;WANG Jun-ke(People’s Hospital of Yubei District,Chongqing 401120)
出处
《湖北中医药大学学报》
2023年第6期26-29,共4页
Journal of Hubei University of Chinese Medicine
基金
重庆市自然科学基金项目(项目编号:cstc2020jcyj-msxmX0233)。
